

North Central Cancer Treatment Group

N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR<sup>®</sup> Depot) for Symptomatic Ascites in Cancer Patients

Update 1 – January 26, 2007

**Summary**

- Protocol resource personnel updates.
- Administrative/editorial changes.

**Replacement pages are included. Please incorporate into the protocol and keep this addendum with your protocol.**

**Title page** Updated to reflect the addition of Update 1 and the current NCI version date.

**Protocol Resources**

Page 2: The following updates have been made:

~~Patricia A. Mann~~ **Laura J. Denton**

NCCTG *Research Base* Protocol Development Coordinator

Phone: (507/284-2172) **538-1802**

Fax: (507/284-5280)

E-mail: [mann.patricia@mayo.edu](mailto:mann.patricia@mayo.edu) [denton.laura@mayo.edu](mailto:denton.laura@mayo.edu)

Barbara Warren

NCCTG *Research Base* Protocol Administration Specialist

Phone: (507/284-5901)

Fax: (507/538-0906)

E-mail: [warren.barbara@mayo.edu](mailto:warren.barbara@mayo.edu)

**Section 14.0 Translational/Pharmacologic Studies**

Page 20: Address and contact information for specimen submission has been updated in Section 14.114 as follows:

MCLCT at Mayo Clinic Rochester will receive the samples and send to the ~~Biospecimen Acquisition Specialist~~ in the Biospecimen, Accessioning, and Processing (BAP) laboratory, ~~Guggenheim 1034~~ **Stabile 13-10A, attention BAP Supervisor.**

Address information has been added to the second sentence of the first paragraph in Section 14.21 as follows:

Ten cc of blood will be collected in purple-top tubes that contain EDTA (plasma) and forwarded to the Biospecimen Accessioning and Processing Laboratory (BAP), **Stabile 13-10A.**